ClinicalTrials.gg
RecruitingNCT06867289DINAMOUpdated Mar 12, 2026

Study of the Efficacy of Moderate Sedation With Intra-NAsal Dexmedetomidine Monitored by EEG MOnitoring

An interventional study of EEG in Procedural Sedation and Analgesia and Pediatric ALL, sponsored by Centre Hospitalier Régional Metz-Thionville. Recruiting at 1 site in France. Open to participants aged 1 Year to 18 Years. Per ClinicalTrials.gov, last updated 2026-03-12.

Sponsored by Centre Hospitalier Régional Metz-Thionville · Not applicable, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Started Apr 2025; still recruiting 1 year 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Not applicable
Ages
1 Year to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 152 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma with a site in France — 29 open to participants now, 40 under way, 13 of them phase 3. Precursor Cell Lymphoblastic Leukemia-Lymphoma · France.

Planned enrollment
82nd of 115
50 · median 96
Started
2025
with 3 others
No phase
13 of 152
3 open now
Primary completion
2027-04
later than 12 of 39 live
Registered
146th of 152
by date

Among the 152 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma with a site in France, this one is the 82nd largest by planned enrollment of the 115 interventional ones that give a count, is one of 4 that started in 2025, is one of 13 with no phase, reaches primary completion later than 12 of the 39 other live ones, and was the 146th registered.

Precursor Cell Lymphoblastic Leukemia-Lymphoma

2,586 studies on the registry are indexed under Precursor Cell Lymphoblastic Leukemia-Lymphoma; 471 are open to participants now.

Browse Precursor Cell Lymphoblastic Leukemia-Lymphoma studies →

Open to participants now

29 of the 152 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma with a site in France are open now. Recruiting first, the newest first:

23 more — sign in →

All 29 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 369 Precursor Cell Lymphoblastic Leukemia-Lymphoma studies recruiting now, 96 (26%) set no upper age limit and 257 (70%) stop at 75 or younger; 247 take children under 18; 29 take healthy volunteers.

This study: 1 Year to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 152 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma with a site in France, or all of them as a file.
02

Study summary

This is a prospective, monocentric diagnostic study aiming to evaluate whether a sedation score obtained by a per-procedural electroencephalogram (EEG), the PSI score, could identify patients for whom a 2 μg/kg dose of DEX would not be sufficient for the successful performance of cerebral NMRI, and who could therefore benefit from a higher dosage of DEX (4 μg/kg).

Read the detailed description

For some children, brain MRI is a particularly important examination for etiological assessment or for monitoring the progress of neurological diseases. It can sometimes be complicated to perform, due to the age and/or pathology of the child concerned. Impossibility, postponement or the need for a general anaesthetic are constraints that should be avoided as far as possible. Procedural sedation with dexmedetomidine (DEX) can be administered intra-nasally. This technique offers good results and safety of use. Nevertheless, the failure rate is 20% to 30%, and may depend on the dosage of DEX used (indicated doses vary from 2 to 4 μg/kg). This study aims to evaluate whether a sedation score obtained by a per-procedural electroencephalogram (EEG), the PSI score, could identify patients for whom a 2 μg/kg dose of DEX would not be sufficient for the successful performance of cerebral NMRI, and who could therefore benefit from a higher dosage of DEX (4 μg/kg).

03

Conditions studied

  • Procedural Sedation and Analgesia
  • Pediatric ALL

Keywords

  • MRI
  • dexmedetomidine
  • EEG
04

Who can participate

Ages eligible
1 Year to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Indication of DEX sedation for brain NMRI at the CHR de Metz-Thionville

    • in a patient aged between 12 months and 5 years or
    • for a patient aged between 5 and 18 whose cooperation during the examination appears compromised (previous failure, autism spectrum disorders, etc.).
  • Membership of a social security scheme
  • Free and obtained from the patient's legal guardian(s).

Exclusion criteria

Exclusion Criteria:

  • Weight \< 10 kg
  • Patients with to the use of DEX

    • to the active ingredient or to any of the listed in the section on "Hypersensitivity".
    • Advanced heart block (level 2 or 3), unless pacemaker implanted
    • Uncontrolled hypotension
    • Acute cerebrovascular pathologies
  • Patients with nasal obstruction
  • Parental refusal of DEX administration
  • Minors under guardianship
  • Minors under judicial sanction
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    EEG Monitoring and PSSS clinical score

    All participants receive an EEG monitoring.

    Device: EEG

Interventions

  • DeviceEEG

    EEG monitoring will be performed in addition to the usual practice, before DEX administration and for 20 minutes before NMRI, to enable calculation of the PSI sedation score (at 0, 10, 20 minutes). Sedation will also be assessed by the PSSS clinical score at 0, 10, 20 minutes after DEX administration, as well as at 150 minutes after DEX.

06

What researchers measure

Primary outcomes

  1. Prediction of complete NMRI success

    To describe the predictive value (ROC curve) of the PSI score assessed 20 minutes after administration of 2 μg/kg of DEX intranasally, for complete success in performing brain NMRI in children under 5 years of age, or over 5 years of age with risk of failure. Successful NMRI is defined as: * Complete if all prescribed sequences can be interpreted without reservation, * Partial if some of the sequences cannot be interpreted or are subject to reservations by the radiologist, * Absent if the examination is cancelled or if all sequences are uninterpretable or subject to reservations. PSI score: evaluated on EEG, the score varies from 0 to 100.

    Time frame: 20 minutes after DEX administration

Secondary outcomes

  1. Complete or partial success in performing brain NMRI in children under 5 years of age, or over 5 years of age with risk of failure.

    Area under the ROC curve for prediction of complete or partial success of NMRI according to PSI score. Successful NMRI is defined as: * Complete if all prescribed sequences can be interpreted without reservation, * Partial if some of the sequences cannot be interpreted or are subject to reservations by the radiologist, * Absent if the examination is cancelled or if all sequences are uninterpretable or subject to reservations.

    Time frame: 20 minutes after DEX administration

  2. Predictive value (ROC curve) of the PSI score for successful completion of brain MRI in children under 5 years of age, or over 5 years of age with risk of failure.

    Area under the ROC curve for prediction of complete success of NMRI according to PSI score by patient age under or over 5 years old Successful NMRI is defined as: * Complete if all prescribed sequences can be interpreted without reservation, * Partial if some of the sequences cannot be interpreted or are subject to reservations by the radiologist, * Absent if the examination is cancelled or if all sequences are uninterpretable or subject to reservations. PSI score: evaluated on EEG, the score varies from 0 to 100.

    Time frame: 20 min after DEX administration

  3. Predictive value (ROC curve) of the PSSS score for successful completion of brain MRI in children under 5 years of age, or over 5 years of age with risk of failure.

    Area under the ROC curve for prediction of complete or partial success of NMRI according to PSSS score at 20 minutes Successful NMRI is defined as: * Complete if all prescribed sequences can be interpreted without reservation, * Partial if some of the sequences cannot be interpreted or are subject to reservations by the radiologist, * Absent if the examination is cancelled or if all sequences are uninterpretable or subject to reservations. PSSS score: ranges from 0 (deepest sedation) to 5 (shallowest sedation) depending on the observation of clinical signs in children

    Time frame: 20 min after DEX administration

  4. Correlation between PSI and PSSS scores

    Describe the correlation between PSI score and PSSS score PSI scores at 0, 10, 20 and 150 minutes after DEX administration and PSSS scores at 0, 10, 20 and 150 minutes after DEX administration

    Time frame: at 0, 10, 20 and 150 minutes after DEX administration

  5. Complications (Quality of recovery)

    PSSS score: ranges from 0 (deepest sedation) to 5 (shallowest sedation) depending on the observation of clinical signs in children

    Time frame: at 150 minutes after DEX administration

  6. Complications (Blood Pressure)

    mmHg

    Time frame: at 0, 10, 20 and 150 minutes after DEX administration

  7. Complications (Heart Rate)

    bpm

    Time frame: at 0, 10, 20 and 150 minutes after DEX administration

  8. Complications (Oxygen Saturation)

    SaO2 (%)

    Time frame: at 0, 10, 20 and 150 minutes after DEX administration

  9. Complications (allergic reactions)

    number and types

    Time frame: at 0, 10, 20 and 150 minutes after DEX administration

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2025 (actual). Primary completion is estimated for Apr 2027, 24 months after the start.

Of 207 non-industry interventional studies with no phase under Precursor Cell Lymphoblastic Leukemia-Lymphoma, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 66. This study's planned 24 months is below that.

Counting every sponsor, half of 214 studies reached it within 32 months; a quarter within 12 and three quarters within 66.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 28, 2025
First posted
Mar 10, 2025
StartActual
Apr 8, 2025
Primary completionEst.
Apr 8, 2027
CompletionEst.
Apr 8, 2027
Last update
Mar 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06867289
Responsible party
Sponsor
First posted
Mar 10, 2025
Start date
Apr 8, 2025
Primary completion
Apr 8, 2027 (estimated)
Completion
Apr 8, 2027 (estimated)
Last update
Mar 12, 2026

Study contacts

Arpiné EL NAR, PhD
Contact
projet-recherche-clinique@chr-metz-thionville.fr
0033387557766
Anne-Charlotte CULLIER, MD
principal investigator · CHR Metz Thionville Hopital Femme Mère Enfant

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion